STK11 and cancer: To examine whether the established HTiP platform40, featuring in vitro cancer- and immune-cell co-culture, could recapitulate LKB1-mut associated immune suppression, we tested the response of LUAD cells with LKB1-mut or WT, to the immune-cell attack.